口服固體製劑市場規模、佔有率、成長分析、按產品類型、按機制、按最終用戶、按地區 - 行業預測，2024-2031

2022年口服固體製劑市場規模將為6066億美元，預測期內（2024-2031年）複合年成長率為6.4%，從2023年的6454.2億美元增至2031年的1.6兆美元。至7000萬美元。

在幾個關鍵因素的推動下，口服固體製劑市場近年來出現了顯著成長。其中包括口服藥物需求的增加、製劑技術的進步以及需要長期藥物治療的人口老化。此外，藥物輸送方法的創新意義重大，可以提高患者的依從性和療效。監管機構為確保品質和安全而實施的嚴格監管正在刺激製藥公司增加研發投資。製藥公司和受託製造廠商之間的合作也有助於擴大產品範圍。簡而言之，隨著醫療保健產業的不斷變化，口服固體製劑市場預計將進一步擴大和發展。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價格分析
• 價值鏈分析
• 市場生態系統
• Start-Ups分析
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 市場魅力指數
• 競爭程度

全球口服固體製劑市場：依產品類型

• 市場概況
• 藥片
  • 常規/立即發布
  • 緩釋製劑
  • 咀嚼錠
  • 發泡
• 膠囊
  • 硬明膠膠囊
  • 軟明膠膠囊
• 粉末/顆粒
• 錠劑
• 軟糖

全球口服固體製劑市場：按機制

• 市場概況
• 控制釋放型
• 立即釋放
• 延遲釋放

全球口服固體製劑市場：依最終用戶分類

• 市場概況
• 主要企業
• 中型企業/中小企業
• 其他（Start-Ups公司/學名藥公司）

全球口服固體製劑市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（United Kingdom）
• Sanofi SA（France）
• Merck & Co., Inc.（United States）
• Johnson & Johnson（United States）
• AstraZeneca PLC（United Kingdom）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bayer AG（Germany）
• Roche Holding AG（Switzerland）
• Bristol Myers Squibb（United States）
• AbbVie Inc.（United States）
• Eli Lilly and Company（United States）
• Boehringer Ingelheim GmbH（Germany）
• Mylan NV（Netherlands）
• Takeda Pharmaceutical Company Limited（Japan）
• Daiichi Sankyo Company, Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Sandoz International GmbH（Germany）

Oral Solid Dosage Pharmaceutical Formulation Market size was valued at USD 606.6 Billion in 2022 and is poised to grow from USD 645.42 Billion in 2023 to USD 1060.17 Billion by 2031, at a CAGR of 6.4% during the forecast period (2024-2031).

The Oral Solid Dosage Pharmaceutical Formulation Market has seen significant growth recently, propelled by several key factors. These include rising demand for oral medications, advancements in drug formulation technologies, and an aging population requiring prolonged pharmaceutical treatment. Moreover, there have been notable innovations in drug delivery methods, leading to enhanced patient compliance and efficacy. Stringent regulations by regulatory bodies ensuring quality and safety have spurred pharmaceutical companies to increase investments in research and development. Collaborations between pharmaceutical firms and contract manufacturing organizations have also been instrumental in broadening product offerings. In summary, the market for oral solid dosage pharmaceutical formulations is set to expand further and evolve amidst ongoing changes in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Oral Solid Dosage Pharmaceutical Formulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Oral Solid Dosage Pharmaceutical Formulation Market Segmental Analysis

The global Oral solid dosage pharmaceutical formulation market is segmented on the basis of product type, mechanism, end-user and region. Based on product type, Tablets (Conventional/Immediate Release, Modified Release, Chewable Tablets, Effervescent Tablets), Capsules (Hard Gelatin Capsules, Soft Gelatin Capsules), Powders & Granules, Lozenges & Pastilles, and Gummies. Based on mechanism, the market is segmented as Controlled-release, Immediate-release, and Delayed-release. Based on end-user, it is segregated into Large-size Companies, Medium- & Small-size Companies, and Others (Startups & Generic Pharmaceutical Companies). Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Oral Solid Dosage Pharmaceutical Formulation Market

Innovations such as 3-D printing, nanotechnology, and advanced drug delivery systems are improving the performance and effectiveness of oral solid dosage medications. These advancements not only enhance patient compliance but also empower pharmaceutical companies to develop new formulations, driving market growth.

Restraints in the Oral Solid Dosage Pharmaceutical Formulation Market

The pharmaceutical industry faces rigorous scrutiny from regulatory agencies worldwide to ensure drug safety and efficacy. These lengthy and complex approval processes can lead to delays in product launches, increased development costs, and hinder market access for new entrants. Meeting these stringent regulatory requirements continues to be a major challenge in the industry.

Market Trends of the Oral Solid Dosage Pharmaceutical Formulation Market

Progress in genetic profiling and biomarker identification has enabled pharmaceutical companies to create medications tailored to the specific needs of individual patients. This development not only improves treatment outcomes but also encourages patient adherence, fostering niche markets for precision oral solid dosage formulations. With the healthcare sector increasingly emphasizing patient-centered approaches, there is anticipated significant growth in demand for personalized oral solid dosage medications.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Oral Solid Dosage Pharmaceutical Market by Product Type

• Market Overview
• Tablets
  • Conventional/Immediate Release
  • Modified Release
  • Chewable Tablets
  • Effervescent Tablets
• Capsules
  • Hard Gelatin Capsules
  • Soft Gelatin Capsules
• Powders & Granules
• Lozenges & Pastilles
• Gummies

Global Oral Solid Dosage Pharmaceutical Market by Mechanism

• Market Overview
• Controlled-release
• Immediate-release
• Delayed-release

Global Oral Solid Dosage Pharmaceutical Market by End User

• Market Overview
• Large-size Companies
• Medium- & Small-size Companies
• Others (Startups & Generic Pharmaceutical Companies)

Global Oral Solid Dosage Pharmaceutical Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments